Loading...
•
Sep 30, 2025
ImmunityBio Q3 2025 Earnings Report
ImmunityBio reported strong quarterly revenue growth as product sales ramped but the company remained unprofitable in Q3 2025.
Key Takeaways
ImmunityBio generated $32060000 in total revenue in Q3 2025 driven by net product sales of ANKTIVA while net loss narrowed compared to the prior year quarter.
Total revenue increased sharply to $32060000 from $6110000 year-over-year. :contentReference[oaicite:0]{index=0}
Product revenue, net in Q3 2025 was approximately $31800000. :contentReference[oaicite:1]{index=1}
Net loss attributable to common stockholders was $67250000. :contentReference[oaicite:2]{index=2}
Diluted loss per share was -$0.07. :contentReference[oaicite:3]{index=3}
Revenue by Segment
Forward Guidance
The company did not provide formal numerical guidance in the Q3 2025 earnings release but continued commentary focused on commercial expansion of ANKTIVA and pipeline development. :contentReference[oaicite:4]{index=4}
Positive Outlook
- Sequential revenue growth reflecting ANKTIVA adoption. :contentReference[oaicite:5]{index=5}
- UK regulatory authorization supporting international expansion. :contentReference[oaicite:6]{index=6}
- Cash and marketable securities increased to $257.8M. :contentReference[oaicite:7]{index=7}
- Strong momentum in payer access and unit sales growth. :contentReference[oaicite:8]{index=8}
- Continued pipeline activity including glioblastoma and NSCLC trials. :contentReference[oaicite:9]{index=9}
Challenges Ahead
- Net loss remains substantial at $67.25M. :contentReference[oaicite:10]{index=10}
- Operating costs and expenses remain significant. :contentReference[oaicite:11]{index=11}
- Liquidity depends on external financing due to cash burn. :contentReference[oaicite:12]{index=12}
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...